Article

ΔFosB: An essential role for ΔFosB in the nucleus accumbens in morphine action

Department of Psychiatry and Center for Basic Neuroscience, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9070, USA.
Nature Neuroscience (Impact Factor: 16.1). 03/2006; 9(2):205-11. DOI: 10.1038/nn1636
Source: PubMed

ABSTRACT

The transcription factor DeltaFosB is induced in the nucleus accumbens (NAc) and dorsal striatum by the repeated administration of drugs of abuse. Here, we investigated the role of DeltaFosB in the NAc in behavioral responses to opiates. We achieved overexpression of DeltaFosB by using a bitransgenic mouse line that inducibly expresses the protein in the NAc and dorsal striatum and by using viral-mediated gene transfer to specifically express the protein in the NAc. DeltaFosB overexpression in the NAc increased the sensitivity of the mice to the rewarding effects of morphine and led to exacerbated physical dependence, but also reduced their sensitivity to the analgesic effects of morphine and led to faster development of analgesic tolerance. The opioid peptide dynorphin seemed to be one target through which DeltaFosB produced this behavioral phenotype. Together, these experiments demonstrated that DeltaFosB in the NAc, partly through the repression of dynorphin expression, mediates several major features of opiate addiction.

Download full-text

Full-text

Available from: Olivier Berton
    • "Similarly, the D 1 R antagonist SCH23390 [(R)-(1)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro- 1H-3-benzazepine hydrochloride] blocked cocaine-(Nye et al., 1995) or morphine-(Muller and Unterwald, 2005) mediated induction of DFosB in the nucleus accumbens and caudateputamen . Transgenic overexpression of DFosB in D 1 R-positive MSNs enhanced the rewarding effects of cocaine (Colby et al., 2003) or morphine (Zachariou et al., 2006a), demonstrating significant functional consequences of the modulation of DFosB expression in these neurons. Dopamine signaling is regulated by the dopamine-and cAMP-regulated phosphoprotein Mr 32 kDa (DARPP-32), which is highly expressed in striatal MSNs and dopaminergic terminal fields (Greengard, 2001b; Nairn et al., 2004). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Δ9-Tetrahydrocannabinol (THC), the main psychoactive component of marijuana, produces motor and motivational effects via interactions with the dopaminergic system in the caudate-putamen and nucleus accumbens. However, the molecular events that underlie these interactions following THC treatment are not well understood. The current study showed that pretreatment with dopamine D1 receptor (D1R) antagonists prior to repeated administration of THC attenuated induction of ΔFosB in the nucleus accumbens, caudate-putamen, amygdala and prefrontal cortex. Anatomical studies showed that repeated THC induced ΔFosB in D1R containing striatal neurons. Dopamine signaling in the striatum involves phosphorylation-specific effects of dopamine- and cAMP-regulated phosphoprotein, Mr 32 kDa (DARPP 32), which regulates protein kinase A signaling. Genetic deletion of DARPP-32 attenuated ΔFosB expression measured after acute, but not repeated, THC administration in both the caudate-putamen and nucleus accumbens. THC was then acutely or repeatedly administered to wild-type and DARPP 32 KO mice, and in vivo responses were measured. DARPP 32 KO mice exhibited enhanced acute THC-mediated hypolocomotion and developed greater tolerance to this response relative to wild-type mice. Agonist-stimulated [35S]GTPγS binding showed that cannabinoid-stimulated G-protein activity did not differ between DARPP 32 KO and wild-type mice treated with vehicle or repeated THC. These results indicate that D1Rs play a major role in THC-mediated ΔFosB induction in the forebrain, whereas the role of DARPP 32 in THC-mediated ΔFosB induction and modulation of motor activity appears to be more complex. The American Society for Pharmacology and Experimental Therapeutics.
    No preview · Article · Jun 2015 · Journal of Pharmacology and Experimental Therapeutics
  • Source
    • "Regulation of PDYN gene expression is a complex phenomenon that may implicate several transcription factors including avian myelocytomatosis viral oncogene homolog (c-Myc), neuron restrictive silencer factor (NRSF)/RE1-silencing transcription factor (REST) [36] [52] [53], USF1/2, AP-1 family protein, FBJ murine osteosarcoma viral oncogene homolog B (FosB), cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB), downstream regulatory element (DRE) antagonist modulator (DREAM), yin-yang1 (YY1) and NF-kB [54] [55] [56] [57]. c-Myc may directly interact with its binding motif in PDYN gene to regulate its function while AP-1 may either interact directly or recruit other proteins to regulate PDYN expression. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Single nucleotide polymorphisms (SNPs) both in coding and non-coding regions govern gene functions prompting differential vulnerability to diseases, heterogeneous response to pharmaceutical regimes and environmental anomalies. These genetic variations, SNPs, may alter an individual's susceptibility for alcohol dependence by remodeling DNA-protein interaction patterns in prodynorphin (PDYN) and the κ-opioid receptor (OPRK1) genes. In order to elaborate the underlying molecular mechanism behind these susceptibility differences we used bioinformatics tools to retrieve differential DNA-protein interactions at PDYN and OPRK1 SNPs significantly associated with alcohol dependence. Our results show allele-specific DNA-protein interactions depicting allele-specific mechanisms implicated in differential regulation of gene expression. Several transcription factors, for instance, VDR, RXR-alpha, NFYA, CTF family, USF-1, USF2, ER, AR and predominantly SP family show an allele-specific binding affinity with PDYN gene; likewise, GATA, TBP, AP-1, USF-2, C/EBPbeta, Cart-1 and ER interact with OPRK1 SNPs on intron 2 in an allele-specific manner. In a nutshell, transition of a single nucleotide may modify differential DNA-protein interactions at OPRK1 and PDYN's SNPs, significantly associated with pathology that may lead to altered individual vulnerability for alcohol dependence.
    Full-text · Article · Oct 2014 · Computers in Biology and Medicine
  • Source
    • "For instance, repeated morphine injections produce a marked decrease in brain μ-opioid receptor (MOP receptor) density (Davis et al., 1979; Tao et al., 1987; Diaz et al., 2000), down-regulation of the high-affinity MOP receptor site in rats and reduction of MOP receptor signalling in sensory neurons and brainstem nuclei (Sim et al., 1996; Johnson et al., 2006). Changes in transcription factor activation following chronic opioid treatment have also been proposed to play a relevant role in opioid tolerance and addiction (Carlezon et al., 2005; Zachariou et al., 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background and purpose: Opioid drugs are potent analgesics. However, their chronic use leads to the rapid development of tolerance to their analgesic effects and subsequent increase of significant side effects, including drug dependence and addiction. Here, we investigated the role of PPARγ in the development of analgesic tolerance to morphine in mice. Experimental approach: We monitored analgesia on alternate days using the tail immersion test. Key results: Daily administration of morphine (30 mg·kg(-1) , bid) resulted in the rapid development of tolerance to thermal analgesia. Co-administration of pioglitazone (10 and 30 mg·kg(-1) , bid) significantly attenuated the development and expression of tolerance. However, pretreatment with GW-9662 (5 mg·kg(-1) , bid), a selective PPARγ antagonist, completely abolished this effect. Injection of GW-9662 and a lower dose of morphine (15 mg·kg(-1) , bid) accelerated the development of tolerance to its antinociceptive effect. Subsequently, we found that conditional neuronal PPARγ knockout (KO) mice develop a more rapid and pronounced tolerance to morphine antinociception compared with wild-type (WT) controls. Moreover, in PPARγ KO mice, pioglitazone was no longer able to prevent the development of morphine tolerance. Conclusions and implications: Overall, our results demonstrate that PPARγ plays a tonic role in the modulation of morphine tolerance, and its pharmacological activation may help to reduce its development. These findings provide new information about the role of neuronal PPARγ and suggest that combining PPARγ agonists with opioid analgesics may reduce the development of tolerance and possibly attenuate the potential for opioid abuse.
    Full-text · Article · Jul 2014 · British Journal of Pharmacology
Show more